{"nct_id":"NCT06208150","title":"A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide","status":"RECRUITING","status_verified_date":"2025-10","start_date":"2024-01-22","start_date_type":"ACTUAL","primary_completion_date":"2026-04-23","primary_completion_date_type":"ESTIMATED","completion_date":"2027-06-27","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["JNJ"]}